How Biotech Startups Use Exosomes for Drug Delivery

For decades, drug delivery has been one of biotech's toughest problems: how do you get a therapeutic molecule to exactly the right cell without it degrading or causing side effects along the way? This episode zooms in on exosomes — tiny lipid vesicles that cells naturally use to communicate — and how a new wave of startups is engineering them as delivery vehicles. Lucas walks through the science: exosomes are about 100 nanometers across, carry proteins and RNA, and can cross biological barriers that synthetic nanoparticles struggle with. He highlights Codiak BioSciences' work on engineered exosomes for oncology and a recent deal between Evox Therapeutics and Eli Lilly worth over a billion dollars in potential milestones. Luna questions whether the manufacturing challenges — scaling up production while maintaining consistency — could stall the field the way they have for cell and gene therapies. They discuss how the first exosome-based therapeutics are nearing clinical data readouts, and what that could mean for the broader drug development landscape. A focused look at a technology that might finally solve the 'right place, right time' problem in medicine. #Exosomes #DrugDelivery #BiotechStartups #CodiakBioSciences #EvoxTherapeutics #EliLilly #RNATherapeutics #Nanoparticles #DrugDevelopment #Oncology #Biotechnology #ClinicalTrials #Pharmaceuticals #TherapeuticDelivery #Business #FexingoBusiness #BiotechBusiness #LifeSciences Keep every episode free: buymeacoffee.com/fexingo